7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 7 of 7 clinical reviews.
Complete regulatory breakdown of Evenity (romosozumab), including FDA approval history, boxed warning details, compounding legality, EMA status, and post-market safety surveillance data.
A clinical review of FDA Adverse Event Reporting System (FAERS) data for romosozumab (Evenity), including cardiovascular safety signals, boxed warning context, and post-market surveillance findings from the ARCH and FRAME trials.
Complete FDA approval timeline for Evenity (romosozumab), including clinical trial data from FRAME and ARCH, boxed warning details, label updates, and post-market safety surveillance.
Complete regulatory overview of Evenity (romosozumab), including FDA approval history, cardiovascular boxed warning, EMA authorization, and country-by-country status for postmenopausal osteoporosis.
A complete timeline of Evenity (romosozumab) FDA label updates from 2020 through 2026, including the cardiovascular boxed warning, post-market safety data, and prescribing changes.
A detailed comparison of how the FDA and EMA evaluated and approved romosozumab (Evenity), including label differences, cardiovascular safety signals from the ARCH trial, and post-market surveillance requirements.
A clinical review of Evenity (romosozumab) patent disputes, FDA regulatory history, boxed warning litigation risk, and the biosimilar pathway for this monoclonal antibody osteoporosis treatment.